Literature DB >> 7526573

Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14.

M Otterlei1, K M Vårum, L Ryan, T Espevik.   

Abstract

Chitosans with different chemical composition were found to induce TNF-alpha production from human monocytes. Their ability to induce TNF-alpha was found to be highly dependent on neutral-solubility and molecular weight. Monoclonal antibodies against CD14 inhibited TNF-alpha production from monocytes stimulated with neutral-soluble chitosans. Binding studies indicated that lipopolysaccharides (LPS) and neutral-soluble chitosans share a binding site on monocytes which involves CD14. TNF-alpha production from monocytes stimulated with chitosans was dependent on serum. LPS-binding protein (LBP) enhanced the chitosan-induced TNF-alpha production only to a minor degree, suggesting that serum proteins other than LBP play an important role in the stimulatory effect.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7526573     DOI： 10.1016/0264-410x(94)90292-5

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

1.  Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor.

Authors:  T G Jahr; L Ryan; A Sundan; H S Lichenstein; G Skjåk-Braek; T Espevik
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

2.  Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses.

Authors:  Xiaoyuan Kong; Gary R Hellermann; Weidong Zhang; Prasanna Jena; Mukesh Kumar; Aruna Behera; Sumita Behera; Richard Lockey; Shyam S Mohapatra
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

3.  Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.

Authors:  Shalini Asthana; Anil K Jaiswal; Pramod K Gupta; Vivek K Pawar; Anuradha Dube; Manish K Chourasia
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

4.  The tumor necrosis factor-inducing potency of lipopolysaccharide and uronic acid polymers is increased when they are covalently linked to particles.

Authors:  G Berntzen; T H Flo; A Medvedev; L Kilaas; G Skjåk-Braek; A Sundan; T Espevik
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

Review 5.  Chitosans for delivery of nucleic acids.

Authors:  Michael D Buschmann; Abderrazzak Merzouki; Marc Lavertu; Marc Thibault; Myriam Jean; Vincent Darras
Journal:  Adv Drug Deliv Rev       Date:  2013-07-18       Impact factor: 15.470

6.  Respiratory syncytial virus infection: from biology to therapy: a perspective.

Authors:  Shyam S Mohapatra; Richard F Lockey
Journal:  World Allergy Organ J       Date:  2008-02       Impact factor: 4.084

7.  Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor.

Authors:  Xiaoqin Wang; Weidong Xu; Subhra Mohapatra; Xiaoyuan Kong; Xu Li; Richard F Lockey; Shyam S Mohapatra
Journal:  Genet Vaccines Ther       Date:  2008-02-15

8.  Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses.

Authors:  T Kusunoki; E Hailman; T S Juan; H S Lichenstein; S D Wright
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

9.  Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma.

Authors:  Mukesh Kumar; Xiaoyuan Kong; Aruna K Behera; Gary R Hellermann; Richard F Lockey; Shyam S Mohapatra
Journal:  Genet Vaccines Ther       Date:  2003-10-27

Review 10.  Chitosan nanoparticles for oral drug and gene delivery.

Authors:  Katherine Bowman; Kam W Leong
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.